Related Experiment Videos
The current cardiac safety situation with antihistamines
1Department of Cardiological Sciences, St George's Hospital Medical School, London, UK.
Summary
Second-generation antihistamines, while generally safe, can pose cardiac risks. Mizolastine, a newer option, shows a favorable cardiac safety profile, offering a potentially safer alternative for allergy treatment.
Area of Science:
- Pharmacology
- Cardiology
- Allergy Treatment
Background:
- First-generation antihistamines cause sedation and anticholinergic effects.
- Second-generation antihistamines were developed to avoid these side effects.
- Concerns exist regarding cardiac risks (dysrhythmias, QT interval prolongation) with some non-sedating antihistamines like terfenadine and astemizole.
Purpose of the Study:
- To evaluate the cardiac safety profile of mizolastine, a new non-sedating antihistamine.
- To compare the cardiac effects of mizolastine with other antihistamines.
- To assess mizolastine's potential as a safe alternative for allergic conditions.
Main Methods:
- Review of clinical studies on mizolastine's effects on QT intervals and dysrhythmias.
- Analysis of mizolastine's pharmacokinetic and physicochemical properties related to cardiac safety.
- Consideration of drug interactions and cytochrome P-450 metabolism.
Main Results:
- Mizolastine demonstrated no dose-related QT interval prolongation in clinical studies.
- No association between mizolastine use and ventricular dysrhythmias was observed.
- Mizolastine has favorable properties including good bioavailability, limited cytochrome P-450 metabolism, and low lipophilicity.
Conclusions:
- Mizolastine appears to offer a safe cardiac profile compared to older non-sedating antihistamines.
- Its low potential for blocking potassium channels suggests cardiac safety advantages.
- Further post-marketing data are needed to confirm the long-term cardiac safety of mizolastine and other newer antihistamines.